On January 5th, the brain-computer interface (BCI) concept suddenly experienced significant movement, with the sector posting substantial gains. Net asset values disclosed that evening revealed that several funds, including BOC Health Life Hybrid and Huayin Health Life Theme, saw single-day net value increases exceeding 10%.
The market widely speculated that these funds might be heavily invested in stocks related to the brain-computer interface sector.
It was learned that fund managers have indeed recently shifted their allocations towards the brain-computer interface space. For instance, BOC Health Life Hybrid, which just underwent a manager change in December 2025, openly stated in its latest letter to investors that it has recently selected the BCI industry as a key focus area.
On the first trading day of 2026 for A-shares, the Shanghai Composite Index once again climbed above the 4000-point mark, with several popular thematic sectors taking turns to perform. Among them, the Brain-Computer Interface Index surged 9.95% on January 5th, while the Memory Index rose by 6.77%.
Coincidentally, the net asset values of multiple funds increased by over 10% on the same day.
Specifically, BOC Health Life Hybrid's net value rose by 10.33%; Huayin Health Life Theme's net value increased by 11.83%; and Founder Fubon Core Advantage Hybrid A's net value grew by 10.02%.
Based on the previous day's sector performance and the latest information, these funds that surged yesterday may include some thematic funds heavily weighted in BCI, such as BOC Health Life Hybrid, while others might be funds heavily invested in storage chips, such as Founder Fubon Core Advantage Hybrid.
Notably, the significant net value increases of these funds have already attracted an influx of some investors. Retail fund investors are actively discussing these products on various third-party platforms and have already identified them as funds targeting specific sectors.
However, this might merely represent short-term bets by fund managers. Holdings could change rapidly with any shift in market sentiment, and investors should remain cautious of the risks when making selections.
Among the mentioned funds, BOC Health Life Hybrid is particularly noteworthy. This fund just changed its fund manager on December 23, 2025, with Wang Fangzhou taking over as the new manager. Although he has been in charge for less than half a month, it is highly likely that he has already made significant changes to the fund's portfolio.
Firstly, judging from the fund's third-quarter 2025 holdings report, its primary allocations were in stocks from sectors like electronics, pharmaceuticals, media, power equipment, and communications. If the portfolio still consisted of these stocks, its net value could not have increased by over 10% on January 5th.
Secondly, following the surge in the BCI sector on January 6th, the fund manager promptly wrote a letter to investors, mentioning the recent selection of the BCI industry as a key focus. This essentially signaled that the fund's heavy investment direction has changed.
Wang Fangzhou pointed out: "The significant rise in the brain-computer interface concept sector was primarily catalyzed by Elon Musk's announcement during the holiday period that he would push for mass production of devices by his affiliated BCI company in 2026, potentially making 2026 the inaugural year for BCI volume. Brain-computer interfaces and their derivative applications could have a massive impact on human society, with a huge potential market."
"From a development stage perspective, the industry is currently on the eve of product commercialization and in a phase of rapid product iteration. For 2026, we may witness several key industry milestones, including product validation and clinical progress in areas like language decoding and visual enhancement for BCI, clinical trials and initial mass production of medical-grade products, changes in capital market investment and financing, and preliminary exploration and deployment of applications in non-serious medical fields. At this stage, product validation and technological breakthroughs remain key to verifying industry development, with major challenges largely being engineering problems."
Wang Fangzhou further stated: "As the industry undergoes accelerated positive changes, capital market attention has significantly increased. The sector has not yet entered a phase of rapid growth, and from a long-term development perspective, pricing is not yet fully reflected. On the other hand, during the early stages of an industry, stock price volatility can be considerable in the short term. BOC Health Life Hybrid has recently selected the BCI industry as a key focus, believing that the growth potential of the BCI industry presents a very attractive long-term investment opportunity. However, the trade-off for these advantages is the incomplete predictability of short-term trends."
Comments